Skip to main content
Sign In
 


 

 Description

 

Dr Reusch made a fundamental observation that CREB, the cAMP Response Element Binding Protein, is a pivotal intermediate through which diabetes, hyperglycemia and oxidative stress exert their detrimental effect on cellular differentiation. Inappropriate regulation of CREB expression and phosphorylation leads to de-differentiation or death of many cells and target organs. She initially identified that insulin promoted CREB activation. This aspect of insulin action is critical for the insulin-induced differentiation of pre-adipocytes into mature adipocytes. Other studies defined a role of CREB in vascular smooth muscle cell (SMC) phenotypic modulation (maintenance of SMC contractile, highly differentiated phenotype). Hyperglycemia, oxidative stress, cytokines, aging, dyslipidemia and insulin resistance lead to a decreased vascular CREB content and CREB-dependent gene expression permitting a proliferative phenotype of SMC. Recently she has observed that intervention with calorie restriction, exercise or insulin sensitizers can restore CREB function in the heart and vasculature. These observations add insight to the mechanism of accelerated atherosclerosis in diabetes.  Her group was the first to describe the role of CREB in neuronal regulation of the bcl-2 gene, an important target for neurotrophin-mediated cytoprotection. CREB prevents programmed cell death in fat cells, neurons and beta cells exposed to pro-apoptotic stimuli such as TNF-a, oxidant and cytokine injury. In addition, she has observed loss of CREB function in the nervous system of diabetic rodents and in the islet of the NOD mouse. 

This body of work lead to the laboratory’s thematic hypothesis:  Diabetes leads to an inappropriate regulation of CREB, which contributes to diabetic complications by loss of differentiation, promotion of apoptosis and ineffective metabolic adaptation. 

We view CREB as a central component of the intercellular cytoprotective homeostatic response to physiological metabolic stress. In this role it supports cell differentiation, contributes to metabolic adaptation and prevents apoptosis.  We postulate that chronic metabolic and inflammatory stress leads to inappropriate downregulation of CREB resulting in dedifferentiation, ineffective metabolic adaptation or death of many cell types and dysfunction of target organs. We propose a model wherein CREB is a key element in what might be termed the Starling Curve of the cellular homeostasis. In this model mild intermittent stress enhances CREB function and cellular defenses and chronic stress leads to CREB dysfunction and cellular dysfunction.  CREB dysfunction in this context may contribute to beta cell failure and the development of diabetes. It may also contribute to the development of diabetic complications in the nervous system, heart and vasculature. Our goal now is to prove the importance of CREB in animal models and explore the impact of interventions that augment CREB function such as exercise, thiazolidinediones and incretins on beta cell failure and neuropathic and vascular complications. In vitro, cytokines and oxidants will not induce apoptosis in neurons or beta cells overexpressing CREB.  If this is the case in vivo, then finding agents or behaviors that increase CREB function will prove an excellent complement to agents that decrease oxidant or cytokine mediated stress. Addressing both sides of this equation simultaneously could contribute to a cure for diabetes and its complications.

Selected Publications 

  • Huebschmann AG, Reis EN, Emsermann C, Dickinson LM, Reusch JE, Bauer TA, Regensteiner JG. Women with type 2 diabetes perceive harder effort during exercise than nondiabetic women. Appl Physiol Nutr Metab. 2009 Oct;34(5):851-7. PUBMED

  • Nadeau KJ, Regensteiner JG, Bauer TA, Brown MS, Dorosz JL, Hull A, Zeitler P, Draznin B, Reusch JE. Insulin Resistance in Adolescents with Type 1 Diabetes and Its Relationship to Cardiovascular Function. J Clin Endocrinol Metab. 2009 PUBMED

  • Pratley RE, Reusch JE, Fleck PR, Wilson CA, Mekki Q; Alogliptin Study 009 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study. Curr Med Res Opin. 2009 Oct;25(10):2361-71. PUBMED

  • Nadeau KJ, Zeitler PS, Bauer TA, Brown MS, Dorosz JL, Draznin B, Reusch JE, Regensteiner JG.Insulin resistance in adolescents with type 2 diabetes is associated with impaired exercise capacity. J Clin Endocrinol Metab. 2009 Oct;94(10):3687-95. PUBMED

  • Regensteiner JG, Bauer TA, Reusch JE, Quaife RA, Chen MY, Smith SC, Miller TM, Groves BM, Wolfel EE. Cardiac dysfunction during exercise in uncomplicated type 2 diabetes. Med Sci Sports Exerc. 2009 May;41(5):977-84. PUBMED

  • Schauer IE, Reusch JE. Nonesterified fatty acid exposure activates protective and mitogenic pathways in vascular smooth muscle cells by alternate signaling pathways. Metabolism. 2009 Mar;58(3):319-27. PUBMED

  • Watson PA, Reusch JE, McCune SA, Leinwand LA, Luckey SW, Konhilas JP, Brown DA, Chicco AJ, Sparagna GC, Long CS, Moore RL. Restoration of CREB Function is Linked to Completion and Stabilization of Adaptive Cardiac Hypertrophy in Response to Exercise. Am J Physiol Heart Circ Physiol. 2007. PUBMED

  • Bauer TA, Reusch JE, Levi M, Regensteiner JG Skeletal Muscle Deoxygenation Following the Onset of Moderate Exercise Suggests Slowed Microvascular Blood Flow Kinetics in Type 2 Diabetes. Diabetes Care. 2007 Aug 3; PUBMED

  • Reusch JE and Draznin B “Atherosclerosis and Insulin Resistance” Diabetes Obesity and Metabolism 1-9, 2006 

Education

Coming Soon!

Reasearch Interests

 

·        Diabetes

·        Vascular Biology

·        Exercise

·        CREB